Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 5, 2015, Pages 298-302

  Antar, Ahmad ^a   Kharfan Dabaja, Mohamed A ^b   Mahfouz, Rami ^a   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

AML; FLT3 ITD; Maintenance; Sorafenib; Stem Cell Transplantation

Indexed keywords

CORTICOSTEROID; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NICOTINAMIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG SAFETY; FLT3 ITD GENE; FOLLOW UP; GENE; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HUMAN; MAINTENANCE THERAPY; MALE; MIDDLE AGED; SALVAGE THERAPY; SKIN GRAFT; TREATMENT OUTCOME; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; GENE DUPLICATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; OFF LABEL DRUG USE; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NIACINAMIDE; OFF-LABEL USE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84928300286     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.12.005     Document Type: Article

References (24)

1. D.G. Gilliland, and J.D. Griffin The roles of FLT3 in hematopoiesis and leukemia Blood 100 2002 1532 1542
2. M. Levis, and D. Small FLT3: ITDoes matter in leukemia Leukemia 17 2003 1738 1752
3. P.D. Kottaridis, R.E. Gale, and M.E. Frew et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
4. S. Frohling, R.F. Schlenk, and J. Breitruck et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm Blood 100 2002 4372 4380
5. C. Thiede, C. Steudel, and B. Mohr et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
6. W.J. Rombouts, I. Blokland, and B. Lowenberg et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene Leukemia 14 2000 675 683
7. M. Bornhauser, T. Illmer, and M. Schaich et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML Blood 109 2007 2264 2265
8. A.E. DeZern, A. Sung, and S. Kim et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution Biol Blood Marrow Transplant 17 2011 1404 1409
9. S. Knapper, K.I. Mills, and A.F. Gilkes et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases Blood 108 2006 3494 3503
10. J. Cortes, J. Foran, and D. Ghirdaladze et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. ASH Annual Meeting Abstracts Blood 114 2009 abstract 636
11. F. Ravandi, J.E. Cortes, and D. Jones et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia J Clin Oncol 28 2010 1856 1862
12. D.A. Macdonald, S.E. Assouline, and J. Brandwein et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186 Leuk Lymphoma 54 2013 760 766
13. H. Serve, U. Krug, and R. Wagner et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial J Clin Oncol 31 2013 3110 3118
14. G. Borthakur, H. Kantarjian, and F. Ravandi et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias Haematologica 96 2011 62 68
15. J. Winkler, D. Rech, and S. Kallert et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report Leuk Res 34 2010 e270 e272
16. M. Sharma, F. Ravandi, and U.D. Bayraktar et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib Biol Blood Marrow Transplant 17 2011 1874 1877
17. S.K. Metzelder, T. Schroeder, and A. Finck et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses Leukemia 26 2012 2353 2359
18. J.M. Llovet, S. Ricci, and V. Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
19. P.P. Zarrinkar, R.N. Gunawardane, and M.D. Cramer et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 114 2009 2984 2992
20. + acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation Blood 119 2012 5133 5143
21. Y. Arima, S. Oshima, and K. Noda et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm J Cardiol 54 2009 512 515
22. I. Porto, A. Leo, and L. Miele et al. A case of variant angina in a patient under chronic treatment with sorafenib Nat Rev Clin Oncol 7 2010 476 480
23. Y.B. Chen, S. Li, and A.A. Lane et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia Biol Blood Marrow Transplant 20 2014 2042 2048
24. S. Brunet, M. Labopin, and J. Esteve et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis J Clin Oncol 30 2012 735 741